Combined hormone therapy and radiation therapy for locally advanced prostate cancer

M Bolla; M Laramas; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME)

doi:10.1016/j.critrevonc.2010.11.003

Combined hormone therapy and radiation therapy for locally advanced prostate cancer

Crit Rev Oncol Hematol. 2012 Dec:84 Suppl 1:e30-4. doi: 10.1016/j.critrevonc.2010.11.003. Epub 2010 Dec 8.

Authors

M Bolla¹, M Laramas; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME)

Affiliation

¹ Radiation Oncology Department, C.H.U. Michallon, Grenoble cedex 9, France [email protected]

PMID: 21144766
DOI: 10.1016/j.critrevonc.2010.11.003

Abstract

The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally advanced prostate cancer. Phase III randomized trials have shown that for locally advanced prostate cancer a 4-month complete androgen blockade initiated 2 months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason score 2-6, meanwhile an adjuvant long term androgen suppression (2.5-3 years) improved significantly overall survival.

Publication types

Review

MeSH terms

Androgen Antagonists / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use*
Chemoradiotherapy / methods
Clinical Trials, Phase III as Topic
Humans
Male
Prostate / drug effects*
Prostate / pathology
Prostate / radiation effects*
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / radiotherapy*
Treatment Outcome

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal